Fredun Pharmaceuticals (BOM:539730) E10: ₹8.39 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:539730 Fredun Pharmaceuticals Ltd BOM:539730
67 GF Score
Price ₹1,442.90
GF Value ₹599.29
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Fredun Pharmaceuticals E10?

Fredun Pharmaceuticals BOM:539730 -0.72% 67 E10 is ₹8.39 as of Jun. 2026. GuruFocus rates BOM:539730 with a GF Score™ of 67/100 and a GF Value™ of ₹599.29 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Fredun Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2026 was ₹7.397. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₹8.39 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average E10 Growth Rate was 36.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Fredun Pharmaceuticals was 36.10% per year. The lowest was 36.10% per year. And the median was 36.10% per year.

As of today (2026-08-19), Fredun Pharmaceuticals's current stock price is ₹1442.90. Fredun Pharmaceuticals's E10 for the quarter that ended in Jun. 2026 was ₹8.39. Fredun Pharmaceuticals's Shiller PE Ratio of today is 171.98.

During the past 13 years, the highest Shiller PE Ratio of Fredun Pharmaceuticals was 184.55. The lowest was 42.05. And the median was 88.69.


Fredun Pharmaceuticals  (BOM:539730) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Fredun Pharmaceuticals's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=1442.90/8.39
=171.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Fredun Pharmaceuticals was 184.55. The lowest was 42.05. And the median was 88.69.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Fredun Pharmaceuticals E10 Related Terms


Fredun Pharmaceuticals E10 Historical Data

* Premium members only.

The historical data trend for Fredun Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fredun Pharmaceuticals E10 Chart

Fredun Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.14 3.04 4.23 0.00 7.66

Fredun Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 6.32 7.07 7.66 8.39

BOM:539730 vs ZTS: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Fredun Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fredun Pharmaceuticals Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fredun Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Fredun Pharmaceuticals's Shiller PE Ratio falls into.


BOM:539730
67GF Score
Fredun Pharmaceuticals Ltd BOM:539730
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fredun Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Fredun Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=7.397/167.3573*167.3573
=7.397

Current CPI (Jun. 2026) = 167.3573.

Fredun Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201609 0.465 105.961 0.734
201612 0.197 105.196 0.313
201703 0.607 105.196 0.966
201706 0.520 107.109 0.812
201709 0.490 109.021 0.752
201712 0.230 109.404 0.352
201803 0.710 109.786 1.082
201806 -0.613 111.317 -0.922
201809 1.880 115.142 2.733
201812 1.427 115.142 2.074
201903 1.070 118.202 1.515
201906 0.197 120.880 0.273
201909 0.733 123.175 0.996
201912 0.850 126.235 1.127
202003 -0.190 124.705 -0.255
202006 0.030 127.000 0.040
202009 0.690 130.118 0.887
202012 1.117 130.889 1.428
202103 -0.153 131.771 -0.194
202106 0.273 134.084 0.341
202109 1.537 135.847 1.894
202112 1.407 138.161 1.704
202203 1.710 138.822 2.061
202206 0.707 142.347 0.831
202209 2.370 144.661 2.742
202212 2.553 145.763 2.931
202303 2.067 146.865 2.355
202306 1.747 150.280 1.946
202309 2.800 151.492 3.093
202312 3.017 152.924 3.302
202403 3.591 153.035 3.927
202406 2.930 155.789 3.148
202409 3.017 157.882 3.198
202412 3.763 158.323 3.978
202503 0.000 157.552 0.000
202506 0.000 159.755 0.000
202509 6.660 162.289 6.868
202512 7.397 163.281 7.582
202603 6.073 164.272 6.187
202606 7.397 167.357 7.397

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ₹8.39 mean?
Fredun Pharmaceuticals (BOM:539730) has a E10 of ₹8.39 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Fredun Pharmaceuticals and its competitors.
Is Fredun Pharmaceuticals' E10 too high?
Fredun Pharmaceuticals' current E10 is ₹8.39. Overall, Fredun Pharmaceuticals has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fredun Pharmaceuticals' E10 compare to ZTS?
Fredun Pharmaceuticals' E10 of ₹8.39 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Fredun Pharmaceuticals and its competitors. Fredun Pharmaceuticals's current E10 is ₹8.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fredun Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Fredun Pharmaceuticals (BOM:539730) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹599.29, compared to a current price of ₹1,442.90 — trading 140.8% above its estimated fair value. The current E10 is ₹8.39. Fredun Pharmaceuticals' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Fredun Pharmaceuticals (BOM:539730), the current E10 is ₹8.39 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fredun Pharmaceuticals (BOM:539730) Overvalued in 2026?

Based on GuruFocus' analysis, Fredun Pharmaceuticals stock appears to be overvalued. The current stock price of ₹1,442.90 is trading 140.8% above its estimated GF Value™ of ₹599.29. GuruFocus considers Fredun Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for BOM:539730:

  • E10: ₹8.39
  • GF Value™: ₹599.29 vs. price of ₹1,442.90 (140.8% above fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the BOM:539730 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fredun Pharmaceuticals Business Description

Address Ganpatrao Kadam Marg, Delisle Road, 11th Floor, Urmi Estate 95, Lower Parel (West), Mumbai, MH, IND, 400013
Fredun Pharmaceuticals Ltd in its Endeavour to move ahead has now ventured into manufacturing of dietary /herbal supplements, nutraceuticals, and other healthcare products along with Animal Healthcare products also with products ranging from allopathic formulations to on field diagnostic kits, Company's main objective is to be a holistic healthcare provider. The group is dedicated to improving lives of people. The Company operates only in a single segment i.e. Pharmaceutical Segment. The company has presence in Domestic as well as International market. The company generates majority of revenue from Domestic market.
67GF Score

Get the complete analysis for BOM:539730

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,442.90
Price
₹599.29
GF Value